Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevaci...
Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
About this item
Full title
Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
Author / Creator
Publisher
Korea (South): The Korean Association for the Study of the Liver
Journal title
Clinical and Molecular Hepatology, 2025, 31(1), , pp.084-086
Language
English
Formats
Publication information
Publisher
Korea (South): The Korean Association for the Study of the Liver
Subjects
More information
Scope and Contents
Contents
KCI Citation Count: 0
Alternative Titles
Full title
Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_10670628
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_10670628
Other Identifiers
ISSN
2287-2728
E-ISSN
2287-285X
DOI
10.3350/cmh.2024.0830
